BMP-2 Osteogenic Composition with NEMO Binding Peptide

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Bone morphogenetic protein-2 (BMP-2) induced soft tissue edema is a significant side effect in bone repair procedures, leading to inflammation and swelling at implantation sites, which current treatments fail to adequately address without causing additional side effects.

Innovation Solution

The use of a composition comprising BMP-2 combined with a NEMO binding domain peptide (NBD) and a biodegradable matrix with a porous collagen surface, where the NBD peptide reduces soft tissue inflammation by inhibiting NFκB activation, thereby minimizing edema.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If BMP-2 is used for bone formation, then bone regeneration is promoted, but soft tissue edema and inflammation occur at the implantation site

Engineering Contradiction:

Improvebone formation rateVSAvoidsoft tissue edema

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a second carrier system that co-delivers anti-edema agents (such as dexamethasone, pentoxifylline, or TGF-beta3) alongside BMP-2. This intermediary approach allows the anti-edema agents to counteract the harmful inflammatory response while BMP-2 continues to promote bone formation, effectively mediating between the beneficial and harmful effects of BMP-2 treatment

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs composite carrier compositions that combine multiple functional materials: a first carrier containing BMP-2 and a second carrier containing anti-edema agents. These composite materials work synergistically to simultaneously achieve bone regeneration and reduce soft tissue edema, transforming a single-function system into a multi-functional therapeutic platform

Inventive Principle:

Principle #40Composite materials

2Strength

If BMP-2 is used for bone repair, then osteoinductive activity is enhanced, but inflammatory response increases

Engineering Contradiction:

Improveosteoinductive activityVSAvoidinflammation

Core Design Contradiction:

StrengthVSObject-generated harmful factors

Solution Approach 1:

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the harmful inflammatory response into a beneficial therapeutic outcome by co-administering anti-edema agents that specifically target and reduce inflammation. The anti-edema agents transform the harmful inflammatory byproduct of BMP-2 treatment into a controlled, manageable response, allowing the full osteoinductive potential of BMP-2 to be realized without excessive inflammation

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination effectively reduces BMP-2 induced soft tissue edema while maintaining bone formation capabilities, as demonstrated by increased bone volume and reduced trabecular spacing in animal models, suggesting a potential therapeutic approach for spinal fusion and other bone repair procedures.

Implementation Method 1

The nuclear factor kB (NFκB) is an essential modulator-binding domain (NEMO binding domain or NBD) and blocks the activation of the IkB kinase (IKK) complex.

Methodology Applied

Scientific EffectProtein-protein interaction inhibition:

Data Source

PatentUS11484575B2Compositions and methods comprising bone morphogenetic protein and NEMO binding peptide

Publication Date: 2022.11.01 WARSAW ORTHOPEDIC INC

AI summary

An osteogenic composition for implantation at or near a target tissue site beneath the skin is provided, the osteogenic composition comprising bone morphogenetic protein and a NEMO binding domain peptide, where the NEMO binding domain peptide reduces soft tissue inflammation at or near the target tissue site. In some embodiments, a method is provided for treating a target tissue site in a patient in need of such treatment, the method comprising implanting an osteogenic composition comprising bone morphogenetic protein and a NEMO binding domain peptide, where the NEMO binding domain peptide reduces soft tissue inflammation at or near the target tissue site.